Mendizabal Adys, Ogilvie Amy C, Bordelon Yvette, Perlman Susan L, Brown Arleen
Department of Neurology (AM, YB, SLP), David Geffen School of Medicine; Institute for Society and Genetics (AM); Interdepartmental Undergraduate Neuroscience Program (AM), UCLA; Division of General Internal Medicine (ACO), Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; Department of Neurology (YB), Cedars Sinai Health Center, Los Angeles, CA; and Division of General Internal Medicine and Health Services Research (AB), Department of Medicine, David Geffen School of Medicine, UCLA.
Neurol Clin Pract. 2024 Oct;14(5):e200344. doi: 10.1212/CPJ.0000000000200344. Epub 2024 Jun 21.
There are well-documented racial and ethnic disparities in access to neurologic care and disease-specific outcomes. Although contemporary clinical and neurogenetic understanding of Huntington disease (HD) is thanks to a decades-long study of a Venezuelan cohort, there are a limited number of studies that have evaluated racial and ethnic disparities in HD. The goal of this study was to evaluate disparities in time from symptom onset to time of diagnosis of HD.
Using the ENROLL-HD periodic data set 5 (PDS5), we performed sequential multivariate linear regressions to evaluate sociodemographic factors associated with disparities in time to diagnosis (TTD) for gene-positive individuals (CAG repeats 36+) in the North America region. Sensitivity analyses included imputed multivariate regression analysis of individuals with a total motor score (TMS) of 10 or higher and those with 40+ CAG repeats. We also used descriptive statistics to present TTD data in other ENROLL-HD participating regions.
Among 4717 gene-positive participants in the North American region, 89.5% identified as White, 3.4% as Hispanic or Latino, and 2.3% as African American/Black. The average TTD in the group was 3.78. When adjusting for clinical and sociodemographic variables, Black participants were diagnosed with HD 1 year later than White participants ( < 0.05). Additional factors associated with a later diagnosis included psychiatric symptoms as initial HD symptom, unemployment during baseline ENROLL visit, and higher educational attainment. Sensitivity analysis of gene-positive (36+ CAG) participants with a TMS of 10 or higher and of those with 40+ CAG repeats yielded similar findings.
Across multiple statistical models, Black ENROLL-HD participants were diagnosed with HD 1 year later than White participants. Clinical factors suggesting a delay in HD diagnosis included psychiatric symptoms at disease onset and a negative family history of HD. Unemployment during baseline visit and higher educational attainment were sociodemographic factors suggestive of a later diagnosis. Additional multicenter qualitative and quantitative studies are needed to better understand reasons for delays in HD diagnosis among Black individuals, and the role of social and structural determinants of health in obtaining a timely HD diagnosis.
在获得神经科护理及疾病特异性结局方面,种族和族裔差异有充分的文献记载。尽管当代对亨廷顿病(HD)的临床和神经遗传学认识得益于对委内瑞拉一个队列长达数十年的研究,但评估HD种族和族裔差异的研究数量有限。本研究的目的是评估从症状出现到HD诊断时间的差异。
使用“亨廷顿病注册研究(ENROLL-HD)”的定期数据集5(PDS5),我们进行了系列多变量线性回归分析,以评估北美地区基因阳性个体(CAG重复序列36+)诊断时间差异(TTD)相关的社会人口学因素。敏感性分析包括对总运动评分(TMS)为10或更高以及CAG重复序列为40+的个体进行多重填补回归分析。我们还使用描述性统计来呈现“亨廷顿病注册研究”其他参与地区的TTD数据。
在北美地区的4717名基因阳性参与者中,89.5%为白人,3.4%为西班牙裔或拉丁裔,2.3%为非裔美国人/黑人。该组的平均TTD为3.78。在对临床和社会人口学变量进行调整后,黑人参与者被诊断为HD的时间比白人参与者晚1年(P<0.05)。与诊断延迟相关的其他因素包括以精神症状作为HD初始症状、在“亨廷顿病注册研究”基线访视期间失业以及较高的教育程度。对TMS为10或更高以及CAG重复序列为40+的基因阳性(36+CAG)参与者进行的敏感性分析得出了类似的结果。
在多个统计模型中,“亨廷顿病注册研究”中的黑人参与者被诊断为HD的时间比白人参与者晚1年。提示HD诊断延迟的临床因素包括疾病发作时的精神症状以及HD的阴性家族史。基线访视期间失业和较高的教育程度是提示诊断延迟的社会人口学因素。需要更多的多中心定性和定量研究,以更好地了解黑人个体HD诊断延迟的原因,以及健康的社会和结构决定因素在及时获得HD诊断中的作用。